DMAC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 16:00):

Stats
Today's Volume	8 740.00
Average Volume	39 550.00
Market Cap	98.31M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.160 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.32
ATR14	$0.0220 (0.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Lorianne Masuoka K.	Buy	285 000	Stock option (right to buy)
2024-01-22	Lorianne Masuoka K.	Buy	0
2024-01-02	Semba Charles Pauling	Buy	9 375	Voting Common Shares, no par value per share
2024-01-02	Kuntz Richard	Buy	14 285	Voting Common Shares, no par value per share
2024-01-02	Pilnik Richard D.	Buy	30 357	Voting Common Shares, no par value per share

INSIDER POWER
53.21
Last 91 transactions
Buy: 8 059 792 \| Sell: 2 870 847

DiaMedica Therapeutics Correlation

10 Most Positive Correlations
GSIT	0.944
APYX	0.943
EXAS	0.942
SPSC	0.94
MDB	0.939
PCYG	0.937
BSY	0.933
IESC	0.933
EWZS	0.931
SGH	0.929

10 Most Negative Correlations
PAIC	-0.931
ONEM	-0.93
BLTE	-0.925
SVOK	-0.922
SOPA	-0.919
ONCR	-0.903
SVAC	-0.899
JRJC	-0.898
CIIG	-0.895
SBNYP	-0.888

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DiaMedica Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2023
Revenue:	$0
Gross Profit:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2022
Revenue:	$0
Gross Profit:	$-25 000.00 (0.00 %)
EPS:	$-0.520

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.